Erdafitinib is Used for treating locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations that has progressed after prior systemic therapy. It was first introduced by Janssen Biotech Inc in its drug Balversa on Apr 12, 2019.

Erdafitinib Patents

Given below is the list of patents protecting Erdafitinib, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Balversa	US11077106	Cancer treatment	Feb 02, 2038	Janssen Biotech
Balversa	US10478494	FGFR/PD-1 combination therapy for the treatment of cancer	Aug 13, 2036	Janssen Biotech
Balversa	US10898482	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	Feb 09, 2036	Janssen Biotech
Balversa	US11684620	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	Feb 09, 2036	Janssen Biotech
Balversa	US12037644	Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor	Oct 18, 2035	Janssen Biotech
Balversa	US9902714	Quinoxaline derivatives useful as FGFR kinase modulators	Mar 26, 2035	Janssen Biotech
Balversa	US8895601	Pyrazolyl quinoxaline kinase inhibitors	Apr 12, 2033	Janssen Biotech
Balversa	US9464071	Pyrazolyl quinoxaline kinase inhibitors	Apr 28, 2031	Janssen Biotech

Add above patents to watchlist

Erdafitinib's Family Patents

Full family tree